9.39

2.29% -0.22

After Hours: 9.38 -0.010 -0.11%

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $9.39, with a volume of 3.33M. It is down -2.29% in the last 24 hours and down -19.47% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Previous Close:

$9.61

Open:

$9.5

24h Volume:

3.33M

Relative Volume:

0.51

Market Cap:

$2.92B

Revenue:

Net Income/Loss:

$-449.64M

P/E Ratio:

-4.192

EPS:

-2.24

Net Cash Flow:

$-405.08M

1W Performance:

-2.80%

1M Performance:

-19.47%

6M Performance:

-36.64%

1Y Performance:

+106.37%

1-Day Range:

$9.335

$9.92

1-Week Range:

$9.12

$9.92

52-Week Range:

$3.21

$18.33

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

557

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

IOVA's Discussions on Twitter

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

12:26 PM

Iovance Biotherapeutics' SWOT analysis: promising launch boosts cancer therapy stock - Investing.com

12:26 PM

03:50 AM

American Century Companies Inc. Decreases Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

03:50 AM

Sep 29, 2024

3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow - MSN

Sep 29, 2024

1,612,055 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by Marshall Wace LLP - MarketBeat

Sep 29, 2024

Sep 27, 2024

Long Focus Capital Management LLC Grows Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Sep 27, 2024

Sep 26, 2024

3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow - AOL

Sep 26, 2024

3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow - Yahoo Finance

Sep 26, 2024

Sep 25, 2024

82,363 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Bought by Magnetar Financial LLC - MarketBeat

Sep 25, 2024

Sep 24, 2024

Brokerages Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $23.00 - MarketBeat

Sep 24, 2024

How the (IOVA) price action is used to our Advantage - Stock Traders Daily

Sep 24, 2024

Sep 23, 2024

Hood River Capital Management LLC Buys 108,189 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Sep 23, 2024

Sep 22, 2024

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is largely controlled by institutional shareholders who own 62% of the company - Simply Wall St

Sep 22, 2024

Seven Eight Capital LP Decreases Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Sep 22, 2024

Sep 20, 2024

Virtu Financial LLC Buys New Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Sep 20, 2024

Sep 17, 2024

Wealthspire Advisors LLC Buys New Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat

Sep 17, 2024

Sep 16, 2024

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.4% - MarketBeat

Sep 16, 2024

Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 74% return over 1 year, surging 4.9% in the last week alone - Yahoo Finance

Sep 16, 2024

3 Things You Need to Know if You Buy Iovance Biotherapeutics Today - Yahoo Finance

Sep 16, 2024

Sep 14, 2024